Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine

Orally available disease-modifying drugs for relapsing-remitting multiple sclerosis (MS) represent an unmet need for this chronic and debilitating disease. Among 5 currently investigated drugs at phase 3 clinical stage, promising efficacy data for fingolimod and oral cladribine have recently been pu...

Descripción completa

Detalles Bibliográficos
Autores principales: Warnke, Clemens, Wiendl, Heinz, Hartung, Hans-Peter, Stüve, Olaf, Kieseier, Bernd C
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2915536/
https://www.ncbi.nlm.nih.gov/pubmed/20689698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2915536/
https://www.ncbi.nlm.nih.gov/pubmed/20689698

Ejemplares similares